A Phase 2 Study of BMY-27557-14 (a Rebeccamycin Analog) in Patients With Ovarian Cancer
OBJECTIVES: I. Determine the response rate to rebeccamycin analogue in patients with
refractory stage III or IV ovarian epithelial cancer who have failed platinum in combination
with paclitaxel chemotherapy. II. Determine the toxicities of this treatment regimen in
OUTLINE: Patients receive rebeccamycin analogue IV over 60 minutes on day 1. Treatment
repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients with complete response after receiving 3 courses receive 3-6 additional courses.
Patients with partial response or stable disease after receiving 3 courses receive 3-12
additional courses. Patients with complete response are followed every 2 months for 2 years,
and then every 3 months thereafter. All other patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 18-39 patients will be accrued for this study.
Primary Purpose: Treatment
David A. Fishman, MD
Robert H. Lurie Cancer Center
United States: Federal Government
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|